7/28, 1:05 PM (Source: TeleTrader)
more TeleTrader news

GSK beats Q2 revenue estimates, EPS

British pharmaceutical company GlaxoSmithKline plc managed to outperform analyst projections with its second-quarter revenue figure on Wednesday, revealing a 12% at CER (constant exchange rates) to £8.1 billion.

Meanwhile, earnings per share (EPS) fell 28% on the year to 27.9p, according to the company's release, which also reaffirmed GSK's 2021 guidance on EPS. GSK's Pharmaceuticals division grew 12% to £4.2 billion in the three months ended June 30, while Vaccines jumped 49% to £1.6 billion.

"We expect this positive momentum to continue through the second half of the year driving us towards the better end of our earnings guidance range for 2021, and meaningful performance improvement in 2022," GSK Chief Executive Emma Walmsley said.

Breaking the News / JC